Brought to you by 
Taisho, Vertex develop caspase inhibitors
Jun 2000
Executive Summary
Taisho and Vertex (small molecule drug discovery) will discover, develop, and market caspase inhibitors to treat cerebrovascular, cardiovascular, and neurodegenerative diseases. The companies will specifically focus on caspases involved in apoptosis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Taisho, Vertex develop caspase inhibitors
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice